| 摘要 |
The disclosure is directed to compounds of formula (I) that are sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme and to pharmaceutically-acceptable salts thereof: wherein the substituents R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are as defined in the specification. These compounds are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. The disclosure further relates to pharmaceutical compositions comprising a compound of formula (I).
|
